C
CG Oncology, Inc. (CGON)
NMS – Real vaqt narxi. Valyuta: USD
71.96
-0.88 (-1.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
71.96
-0.00 (-0.00%)
Bozordan keyin: Jun 26, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NMS – Real vaqt narxi. Valyuta: USD
71.96
-0.88 (-1.21%)
Yopilishda: Jun 26, 2026, 4:00 PM EDT
71.96
-0.00 (-0.00%)
Bozordan keyin: Jun 26, 2026, 4:34 PM EDT
CG Oncology, Inc., kechki bosqichdagi klinik biofarmatsevtika kompaniyasi, Qo'shma Shtatlardagi siydik pufagi saratoni bilan og'rigan bemorlar uchun kretostimogen grenadenorepvecni ishlab chiqadi va tijoratlashtiradi. Kompaniyaning mahsulot nomzodi kretostimogendir, bu tekshiruv ostidagi onkolitik immunoterapiya bo'lib, u BCG muvaffaqiyatsiz tugaganidan keyin yuqori xavfli NMIBC bemorlarida kretostimogenning 2-faza klinik sinovlarida; yuqori xavfli BCG-reaktiv bo'lmagan, CISni o'z ichiga olgan NMIBC va BCG-reaktiv bo'lmagan Ta yoki T1 papillari o'smalari bilan og'rigan bemorlarni davolashda monoterapiya sifatida kretostimogenning xavfsizligi va samaradorligini baholash uchun 3-faza klinik sinovlarida; yolg'iz vosita sifatida 3-faza BOND-003 Cohort C sinovlarida; BCG-UR papillari-faqat NMIBC bemorlarida yolg'iz vosita sifatida 3-faza BOND-003 Cohort P sinovlarida. Shuningdek, u TURBT dan keyin o'rtacha xavfli NMIBC uchun kretostimogen monoterapiyasini ishlab chiqadi, bu adjuvant kretostimogenning xavfsizligi va samaradorligini baholash uchun 3-faza PIVOT-006 klinik sinovlarida; va yuqori xavfli NMIBC uchun kretostimogen monoterapiyasini 2-faza CORE-008 klinik sinovlarida yuqori xavfli NMIBC, shu jumladan BCG bilan aloqada bo'lgan va BCG-naïve NMIBC bemorlarini davolashda kretostimogenning xavfsizligi va klinik natijalarini baholash uchun. Kompaniya ilgari Cold Genesys, Inc. nomi bilan tanilgan va 2020 yil iyun oyida CG Oncology, Inc. nomiga o'zgartirilgan. CG Oncology, Inc. 2010 yilda tashkil etilgan va shtab-kvartirasi Dallas, Texasda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Vijay Kasturi M.D. | Chief Medical Officer |
| Mr. Ambaw Bellete M.S. | Chief Operating Officer |
| Mr. Arthur Kuan | Chairman, President & CEO |
| Mr. Bing Kung | Vice President of Corporate Development |
| Mr. James M. DeTore | Chief Financial Officer |
| Mr. Joshua F. Patterson | General Counsel, Chief Compliance Officer & Secretary |
| Mr. Swapnil Bhargava Ph.D. | Chief Technical Officer |
| Ms. Amy Steele | Vice President of Finance & Administration |
| Ms. Sarah Connors | Vice President of Communications & Patient Advocacy |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-06-08 | 8-K | d54487d8k.htm |
| 2026-05-26 | 8-K | ck0001991792-20260520.htm |
| 2026-05-08 | 8-K | ck0001991792-20260508.htm |
| 2026-05-08 | 10-Q | ck0001991792-20260331.htm |
| 2026-04-24 | DEFA14A | cgon_defa14a_4.2026.htm |
| 2026-04-24 | DEF 14A | ck0001991792-20260423.htm |
| 2026-04-24 | ARS | cgon_ars_12.31.2025.pdf |
| 2026-04-13 | 8-K | ck0001991792-20260413.htm |
| 2026-02-27 | S-8 | ck0001991792-20260227.htm |
| 2026-02-27 | 8-K | ck0001991792-20260227.htm |